GSK Reaffirms 2026 Guidance With 3%-5% Turnover Growth And 7%-9% Core EPS Growth, Eyes £40B+ Sales By 2031
غلاكسو سميث كلاين
GlaxoSmithKline plc Sponsored ADR GSK | 0.00 |
2026 guidance and 2031 sales outlook reaffirmed • Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9% • 2031 sales outlook of more than £40 billion